MX2017013643A - Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz. - Google Patents
Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.Info
- Publication number
- MX2017013643A MX2017013643A MX2017013643A MX2017013643A MX2017013643A MX 2017013643 A MX2017013643 A MX 2017013643A MX 2017013643 A MX2017013643 A MX 2017013643A MX 2017013643 A MX2017013643 A MX 2017013643A MX 2017013643 A MX2017013643 A MX 2017013643A
- Authority
- MX
- Mexico
- Prior art keywords
- fixed dose
- tamper
- drugs
- matrix
- particles
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15165070 | 2015-04-24 | ||
| PCT/EP2016/058977 WO2016170093A1 (en) | 2015-04-24 | 2016-04-22 | Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a matrix |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017013643A true MX2017013643A (es) | 2018-03-08 |
Family
ID=53015581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017013643A MX2017013643A (es) | 2015-04-24 | 2016-04-22 | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20160310486A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3285744A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2018513864A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016251302A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017022335A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2983648A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2017013643A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016170093A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3473246A1 (en) | 2017-10-19 | 2019-04-24 | Capsugel Belgium NV | Immediate release abuse deterrent formulations |
| WO2019126125A1 (en) | 2017-12-20 | 2019-06-27 | Purdue Pharma L.P. | Abuse deterrent morphine sulfate dosage forms |
| EP3679926A1 (en) * | 2019-01-14 | 2020-07-15 | APTYS Pharmaceuticals SAS | A method of manufacturing a pharmaceutical composition comprising nefopam and acetaminophen, and the pharmaceutical composition obtained thereby |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7141250B2 (en) | 2001-08-06 | 2006-11-28 | Euro-Celtique S.A. | Pharmaceutical formulation containing bittering agent |
| US20030092724A1 (en) | 2001-09-18 | 2003-05-15 | Huaihung Kao | Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| US20070183980A1 (en) | 2003-08-06 | 2007-08-09 | Elisabeth Arkenau-Maric | Dosage form that is safeguarded from abuse |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| US7201920B2 (en) | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
| EP1740156B8 (de) | 2004-04-22 | 2012-07-11 | Grünenthal GmbH | Verfahren zur herstellung einer gegen missbrauch gesicherten, festen darreinchungsform |
| AR049839A1 (es) | 2004-07-01 | 2006-09-06 | Gruenenthal Gmbh | Procedimiento para la produccion deuna forma farmaceutica solida, protegida frente al abuso |
| WO2006002886A1 (de) | 2004-07-01 | 2006-01-12 | Grünenthal GmbH | Gegen missbrauch gesicherte, orale darreichungsform enthaltend (1r, 2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol |
| FI1765303T4 (fi) | 2004-07-01 | 2023-01-31 | Väärinkäytöltä suojattu oraalinen tabletti | |
| DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| WO2006122021A1 (en) | 2005-05-10 | 2006-11-16 | Novartis Ag | Extrusion process for making compositions with poorly compressible therapeutic compounds |
| US8652529B2 (en) | 2005-11-10 | 2014-02-18 | Flamel Technologies | Anti-misuse microparticulate oral pharmaceutical form |
| US20070292508A1 (en) | 2006-06-05 | 2007-12-20 | Balchem Corporation | Orally disintegrating dosage forms |
| US20080069891A1 (en) | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
| SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
| DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
| EP2249811A1 (en) | 2008-01-25 | 2010-11-17 | Grünenthal GmbH | Pharmaceutical dosage form |
| KR101690094B1 (ko) | 2008-05-09 | 2016-12-27 | 그뤼넨탈 게엠베하 | 분무 응결 단계의 사용하에 중간 분말 제형 및 최종 고체 제형을 제조하는 방법 |
| GB0909680D0 (en) | 2009-06-05 | 2009-07-22 | Euro Celtique Sa | Dosage form |
| AR077493A1 (es) | 2009-07-22 | 2011-08-31 | Gruenenthal Gmbh | Composicion farmaceutica extruida en caliente con liberacion controlada. procedimiento de preparacion |
| SI2456424T1 (sl) | 2009-07-22 | 2013-10-30 | Gruenenthal Gmbh | Oksidacijsko stabilizirana odmerna oblika, varna pred zlorabo |
| EP2531176B1 (en) | 2010-02-03 | 2016-09-07 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of an extruder |
| MX2013002377A (es) | 2010-09-02 | 2013-04-29 | Gruenenthal Gmbh | Forma de dosificacion resistente a manipulacion que comprende una sal inorganica. |
| JP5925778B2 (ja) | 2010-09-02 | 2016-05-25 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | アニオン性ポリマーを含む不正使用抵抗性剤形 |
| PL2611425T3 (pl) | 2010-09-02 | 2014-09-30 | Gruenenthal Gmbh | Odporna na ingerencję postać dawki zawierająca polimer anionowy |
| EP2635258A1 (en) | 2010-11-04 | 2013-09-11 | AbbVie Inc. | Drug formulations |
| US8858963B1 (en) * | 2011-05-17 | 2014-10-14 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
| JP2014524925A (ja) | 2011-07-29 | 2014-09-25 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 即時薬剤放出を提供するタンパーレジスタント錠剤 |
| EP2736497B1 (en) | 2011-07-29 | 2017-08-23 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
| FR2979242A1 (fr) | 2011-08-29 | 2013-03-01 | Sanofi Sa | Comprime contre l'usage abusif, a base de paracetamol et d'oxycodone |
| AR088250A1 (es) | 2011-10-06 | 2014-05-21 | Gruenenthal Gmbh | Forma de dosificacion farmaceutica oral resistente a alteracion comprendiendo agonista opioide y antagonista opioide |
| MX349725B (es) | 2011-11-17 | 2017-08-10 | Gruenenthal Gmbh | Forma de dosificacion farmaceutica oral a prueba de manipulacion que comprende un agente antagonista y/o aversivo opioide, oxido de polialquileno y un polimero anionico. |
| MX356421B (es) | 2012-02-28 | 2018-05-29 | Gruenenthal Gmbh | Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico. |
| EP2819657A1 (en) | 2012-02-28 | 2015-01-07 | Grünenthal GmbH | Tamper-resistant pharmaceutical dosage form comprising nonionic surfactant |
| EP3170492B1 (en) * | 2012-03-02 | 2020-07-08 | Rhodes Pharmaceuticals L.P. | Tamper resistant immediate release formulations |
| AR090695A1 (es) | 2012-04-18 | 2014-12-03 | Gruenenthal Gmbh | Forma de dosificacion farmaceutica resistente a la adulteracion y resistente a la liberacion inmediata de la dosis |
| PT2846835T (pt) | 2012-05-11 | 2017-12-15 | Gruenenthal Gmbh | Forma farmacêutica termoformada, resistente à adulteração contendo zinco |
| CA2903200A1 (en) * | 2013-03-15 | 2014-09-25 | Mallinckrodt Llc | Compositions comprising an opioid and an additional active pharmaceutical ingredient for rapid onset and extended duration of analgesia that may be administered without regard to food |
| MX371432B (es) | 2013-05-29 | 2020-01-30 | Gruenenthal Gmbh | Forma de dosificacion resistente al uso indebido que contiene una o mas particulas. |
| US9737490B2 (en) * | 2013-05-29 | 2017-08-22 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
| CA2817728A1 (en) | 2013-05-31 | 2014-11-30 | Pharmascience Inc. | Abuse deterrent immediate release formulation |
| EA032465B1 (ru) | 2013-07-12 | 2019-05-31 | Грюненталь Гмбх | Защищенная от применения не по назначению пероральная фармацевтическая лекарственная форма, содержащая этиленвинилацетатный полимер, и способ ее изготовления |
-
2016
- 2016-04-22 WO PCT/EP2016/058977 patent/WO2016170093A1/en not_active Ceased
- 2016-04-22 AU AU2016251302A patent/AU2016251302A1/en not_active Abandoned
- 2016-04-22 BR BR112017022335A patent/BR112017022335A2/pt active Search and Examination
- 2016-04-22 JP JP2017554855A patent/JP2018513864A/ja not_active Withdrawn
- 2016-04-22 MX MX2017013643A patent/MX2017013643A/es unknown
- 2016-04-22 EP EP16717944.9A patent/EP3285744A1/en not_active Withdrawn
- 2016-04-22 CA CA2983648A patent/CA2983648A1/en not_active Abandoned
- 2016-04-22 US US15/135,588 patent/US20160310486A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2983648A1 (en) | 2016-10-27 |
| JP2018513864A (ja) | 2018-05-31 |
| US20160310486A1 (en) | 2016-10-27 |
| AU2016251302A1 (en) | 2017-11-23 |
| BR112017022335A2 (pt) | 2018-07-10 |
| EP3285744A1 (en) | 2018-02-28 |
| WO2016170093A1 (en) | 2016-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017013636A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas. | |
| MX390954B (es) | Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo. | |
| BR112017014067A2 (pt) | composição para tratar doenças relacionadas a il-6 | |
| MX390570B (es) | Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo. | |
| MX392839B (es) | Liberacion autorregulada de ingrediente farmaceutico activo. | |
| UY35907A (es) | Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmaceuticas que las contienen, así como su uso para la preparación de medicamentos | |
| CL2015002733A1 (es) | Composición farmacéutica de clorhidrato de s-cetamina. | |
| MX2019003467A (es) | Formulaciones y metodos para la administracion vaginal de antiprogestinas. | |
| MX2017000627A (es) | Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe). | |
| GT201400059A (es) | Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| BR112015030315A2 (pt) | derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo | |
| CO6640305A2 (es) | Elaboración de gránulos sin activos y tabletas que comprenden los mismos | |
| AR094289A1 (es) | Sistemas de administracion transdermica de farmacos para levonorgestrel y etinil estradiol | |
| EA201501164A1 (ru) | Твердая фармацевтическая лекарственная форма | |
| MX2017013643A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz. | |
| UY35890A (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington | |
| MX2017013634A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y un polvo. | |
| MX2017013633A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas. | |
| BR112014024033A8 (pt) | Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes | |
| ECSP16005208A (es) | Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación | |
| CL2019003463A1 (es) | Composición farmacéutica y forma de dosis farmacéutica que comprenden (e)-4-(2-(aminometil)-3-fluoroaliloxi)-n-ter-butilbenzamida, proceso para su preparación, métodos para tratamiento y usos de estas. | |
| MX2018005439A (es) | Compuestos oxadiazoespiricos para el tratamiento del abuso y la adiccion a las drogas. | |
| MX391191B (es) | Composiciones de liberación extendida de onapristona y métodos. | |
| CL2016000183A1 (es) | Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido redispersable que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación |